Iradimed (NASDAQ:IRMD) Issues Quarterly Earnings Results, Beats Estimates By $0.12 EPS
Iradimed (NASDAQ:IRMD) issued its quarterly earnings data on Thursday. The medical equipment provider reported $0.05 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.07) by $0.12, MarketWatch Earnings reports. The business had revenue of $6.80 million during the quarter, compared to the consensus estimate of $5.53 million. Iradimed had a net margin of 14.74% and a return on equity of 9.71%.
NASDAQ IRMD traded down $0.99 on Friday, hitting $22.28. The company’s stock had a trading volume of 29,364 shares, compared to its average volume of 38,552. The company has a quick ratio of 11.54, a current ratio of 12.40 and a debt-to-equity ratio of 0.05. Iradimed has a 1-year low of $14.41 and a 1-year high of $28.43. The company’s 50-day moving average is $23.56 and its 200 day moving average is $22.77. The firm has a market cap of $268.47 million, a PE ratio of 51.81 and a beta of 1.37.
Several equities analysts recently commented on IRMD shares. Zacks Investment Research downgraded shares of Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, July 1st. BidaskClub downgraded shares of Iradimed from a “hold” rating to a “sell” rating in a research note on Tuesday, July 14th. Roth Capital dropped their price objective on shares of Iradimed from $32.00 to $30.00 in a research note on Tuesday, April 14th. Finally, ValuEngine cut shares of Iradimed from a “buy” rating to a “hold” rating in a research report on Friday, May 1st.
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.
Read More: Debt-To-Equity Ratio
Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.